Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311032 · ClinicalTrials.gov registry record
Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas
A clinical trial of Surgery Risk Assessment, sponsored by NYU Langone Health.
- Completed
- Registry status
- 72
- Enrollment target
- 1
- Study location
NCT06311032: Completed study of Surgery Risk Assessment, sponsored by NYU Langone Health.
NCT06311032 is a study of Surgery Risk Assessment that has completed, run by NYU Langone Health. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06311032, a study of Surgery Risk Assessment, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.
Conditions Studied
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-03-29 |
| Est. Completion | 2023-07-28 |
What the finished NCT06311032 record still lists
NCT06311032 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target.
The record links to 1 condition, with Surgery Risk Assessment appearing as the primary indexed condition, and to 0 interventions.
NCT06311032 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06311032 about?
NCT06311032 is a clinical study titled "Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas". The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.
What is the current status of trial NCT06311032?
This trial is currently completed. The enrollment target is 72 participants. The study started on 2023-03-29. Estimated completion is 2023-07-28.
What conditions does trial NCT06311032 study?
This clinical trial studies the following conditions: Surgery Risk Assessment.
Who is sponsoring clinical trial NCT06311032?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06311032 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI